$FATE
Fate Therapeutics Inc

2016 Q1 Form 10-Q Financial Statement

#000156459016018578 Filed on May 09, 2016

View on sec.gov

Income Statement

Concept 2016 Q1 2015 Q1
Revenue $1.322M $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.600M $2.760M
YoY Change -5.8% 14.05%
% of Gross Profit
Research & Development $6.636M $4.568M
YoY Change 45.27% 1.02%
% of Gross Profit
Depreciation & Amortization $227.0K $128.0K
YoY Change 77.34% 4.07%
% of Gross Profit
Operating Expenses $9.238M $7.324M
YoY Change 26.13% 5.58%
Operating Profit -$7.916M -$7.324M
YoY Change 8.08% 5.58%
Interest Expense $488.0K $558.0K
YoY Change -12.54% 1197.67%
% of Operating Profit
Other Income/Expense, Net -$461.0K -$557.0K
YoY Change -17.24% 1195.35%
Pretax Income -$8.380M -$7.880M
YoY Change 6.35% 12.89%
Income Tax
% Of Pretax Income
Net Earnings -$8.377M -$7.881M
YoY Change 6.29% 12.91%
Net Earnings / Revenue -633.66%
Basic Earnings Per Share
Diluted Earnings Per Share -$291.2K -$383.5K
COMMON SHARES
Basic Shares Outstanding 28.86M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q1 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $55.60M $42.30M
YoY Change 31.44% -11.69%
Cash & Equivalents $39.49M $42.35M
Short-Term Investments $16.10M
Other Short-Term Assets $1.000M $400.0K
YoY Change 150.0% 0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $56.60M $42.80M
YoY Change 32.24% -11.32%
LONG-TERM ASSETS
Property, Plant & Equipment $2.000M $1.500M
YoY Change 33.33% 18.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $200.0K
YoY Change -50.0% 100.0%
Total Long-Term Assets $2.100M $1.700M
YoY Change 23.53% 22.66%
TOTAL ASSETS
Total Short-Term Assets $56.60M $42.80M
Total Long-Term Assets $2.100M $1.700M
Total Assets $58.70M $44.50M
YoY Change 31.91% -10.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.000M $1.300M
YoY Change 53.85% -2.26%
Accrued Expenses $2.000M $1.800M
YoY Change 11.11% 9.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $7.700M $3.300M
YoY Change 133.33% 166.13%
Total Short-Term Liabilities $13.90M $6.400M
YoY Change 117.19% 46.99%
LONG-TERM LIABILITIES
Long-Term Debt $8.700M $16.40M
YoY Change -46.95%
Other Long-Term Liabilities $5.400M $400.0K
YoY Change 1250.0% 300.0%
Total Long-Term Liabilities $14.10M $16.80M
YoY Change -16.07% 16700.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.90M $6.400M
Total Long-Term Liabilities $14.10M $16.80M
Total Liabilities $28.00M $23.20M
YoY Change 20.69% 415.56%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $30.70M $21.30M
YoY Change
Total Liabilities & Shareholders Equity $58.70M $44.50M
YoY Change 31.91% -10.37%

Cashflow Statement

Concept 2016 Q1 2015 Q1
OPERATING ACTIVITIES
Net Income -$8.377M -$7.881M
YoY Change 6.29% 12.91%
Depreciation, Depletion And Amortization $227.0K $128.0K
YoY Change 77.34% 4.07%
Cash From Operating Activities -$7.250M -$6.380M
YoY Change 13.64% 21.29%
INVESTING ACTIVITIES
Capital Expenditures $178.0K $452.0K
YoY Change -60.62% 13.57%
Acquisitions
YoY Change
Other Investing Activities -$16.17M
YoY Change
Cash From Investing Activities -$16.34M -$450.0K
YoY Change 3531.11% 12.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $1.873M
YoY Change
Cash From Financing Activities -1.730M 80.00K
YoY Change -2262.5% -116.0%
NET CHANGE
Cash From Operating Activities -7.250M -6.380M
Cash From Investing Activities -16.34M -450.0K
Cash From Financing Activities -1.730M 80.00K
Net Change In Cash -25.32M -6.750M
YoY Change 275.11% 9.58%
FREE CASH FLOW
Cash From Operating Activities -$7.250M -$6.380M
Capital Expenditures $178.0K $452.0K
Free Cash Flow -$7.428M -$6.832M
YoY Change 8.72% 20.75%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4568000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
7324000
CY2015Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000
CY2015Q1 us-gaap Interest Expense
InterestExpense
558000
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-557000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-7881000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2756000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7324000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6636000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2602000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
9238000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-25322000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7916000
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
27000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
75000
CY2016Q1 us-gaap Interest Expense
InterestExpense
488000
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-461000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-8377000
CY2016Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
14000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-8363000
CY2015Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-7881000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28777790
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20554478
CY2016Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
227000
CY2015Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
128000
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
797000
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
608000
CY2016Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
40000
CY2015Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
44000
CY2016Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-55000
CY2016Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
157000
CY2015Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
164000
CY2016Q1 us-gaap Straight Line Rent
StraightLineRent
7000
CY2015Q1 us-gaap Straight Line Rent
StraightLineRent
10000
CY2016Q1 fate Deferred Revenue Expense
DeferredRevenueExpense
822000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
112000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-303000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
790000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
269000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7252000
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6375000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
178000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
452000
CY2016Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
16166000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-16344000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-452000
CY2016Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
147000
CY2015Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
75000
CY2016Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1873000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-1726000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6752000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49101000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42349000
CY2016Q1 us-gaap Revenue Recognition Milestone Method Factors
RevenueRecognitionMilestoneMethodFactors
(i) persuasive evidence that an agreement exists; (ii) delivery of the products and/or services has occurred; (iii) the selling price is fixed or determinable; and (iv) collectability is reasonably assured.
CY2016Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
16111000
CY2016Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
14000
CY2016Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
4500000
CY2016Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company&#8217;s consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;). The preparation of the Company&#8217;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#8217;s consolidated financial statements relate to accrued expenses. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</p></div>
CY2016Q1 fate Common Stock Issuable Upon Exercise Of Outstanding Options
CommonStockIssuableUponExerciseOfOutstandingOptions
4400000
CY2015Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
3100000
CY2015Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
3000000
CY2016Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
16125000
CY2016Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2016Q1 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2016Q1 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2016Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2016Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2016Q1 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2016Q1 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2016Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
792000
CY2015Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
993000
CY2016Q1 fate Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
492000
CY2015Q4 fate Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
446000
CY2016Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
754000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1000000
CY2016Q1 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
37641
CY2016Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
16581000
CY2015Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
18454000
CY2016Q1 fate Debt Instrument Discount Non Current
DebtInstrumentDiscountNonCurrent
53000
CY2015Q4 fate Debt Instrument Discount Non Current
DebtInstrumentDiscountNonCurrent
77000
CY2016Q1 fate Long Term Debt Net Of Long Term Portion Of Debt Issuance Costs And Discounts
LongTermDebtNetOfLongTermPortionOfDebtIssuanceCostsAndDiscounts
16528000
CY2015Q4 fate Long Term Debt Net Of Long Term Portion Of Debt Issuance Costs And Discounts
LongTermDebtNetOfLongTermPortionOfDebtIssuanceCostsAndDiscounts
18377000
CY2016Q1 fate Long Term Debt Gross Current
LongTermDebtGrossCurrent
7828000
CY2015Q4 fate Long Term Debt Gross Current
LongTermDebtGrossCurrent
7689000
CY2016Q1 fate Debt Instrument Discount Current
DebtInstrumentDiscountCurrent
123000
CY2015Q4 fate Debt Instrument Discount Current
DebtInstrumentDiscountCurrent
139000
CY2016Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
500000
CY2015Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
600000
CY2016Q1 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
100000

Files In Submission

Name View Source Status
0001564590-16-018578-index-headers.html Edgar Link pending
0001564590-16-018578-index.html Edgar Link pending
0001564590-16-018578.txt Edgar Link pending
0001564590-16-018578-xbrl.zip Edgar Link pending
fate-10q_20160331.htm Edgar Link pending
fate-20160331.xml Edgar Link completed
fate-20160331.xsd Edgar Link pending
fate-20160331_cal.xml Edgar Link unprocessable
fate-20160331_def.xml Edgar Link unprocessable
fate-20160331_lab.xml Edgar Link unprocessable
fate-20160331_pre.xml Edgar Link unprocessable
fate-ex311_8.htm Edgar Link pending
fate-ex321_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending